Valacyclovir: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: DNA polymerase Inhibitor | ||
*Dosage Forms: 500, 1000 | *Dosage Forms: 500 mg, 1000 mg | ||
*Common Trade Names: Valtrex | *Common Trade Names: Valtrex | ||
| Line 7: | Line 7: | ||
===[[HSV-1]]=== | ===[[HSV-1]]=== | ||
* Acute episode: 2000 mg PO BID x 1 day | * Acute episode: 2000 mg PO BID x 1 day | ||
* Suppression: 500 mg PO | * Suppression: 500 mg PO daily | ||
===Genital HSV=== | ===Genital HSV=== | ||
*1st episode: 1000 mg PO BID x 7-10 days, start within 48-72 hour of symptoms | *1st episode: 1000 mg PO BID x 7-10 days, start within 48-72 hour of symptoms | ||
* | *Recurrence: 500 mg PO BID x 3 days, alternative: 1000 mg PO daily x 5 days | ||
===[[Herpes zoster]]=== | ===[[Herpes zoster]]=== | ||
*1000 mg PO TID x 7 days | *1000 mg PO TID x 7 days | ||
| Line 16: | Line 16: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Genital HSV=== | ===Genital HSV=== | ||
* | *Same as adult dosing for adolescents | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: Safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult: | **Adult: | ||
**Pediatric | **Pediatric | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult: | **Adult: Not defined | ||
**Pediatric: | **Pediatric: Not defined | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
* | *Caution with any renal impairment | ||
*Caution with geriatric patients and reduced GFR | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
* | *Acute renal failure | ||
* | *Thrombocytopenia | ||
* | *Aplastic anemia | ||
* | *Delirium | ||
* | *Psychosis | ||
* | *Seizures | ||
===Common=== | ===Common=== | ||
* | *Nausea/vomiting | ||
* | *Headache | ||
* | *Abdominal pain | ||
* | *Depression | ||
* | *Elevated LFT's | ||
* | *Fatigue | ||
==Pharmacology== | ==Pharmacology== | ||
| Line 52: | Line 53: | ||
*Metabolism: GI tract, liver | *Metabolism: GI tract, liver | ||
*Excretion: feces, urine | *Excretion: feces, urine | ||
*Mechanism of Action: | *Mechanism of Action: DNA polymerase Inhibitor | ||
==See Also== | ==See Also== | ||
Revision as of 21:09, 3 April 2015
General
- Type: DNA polymerase Inhibitor
- Dosage Forms: 500 mg, 1000 mg
- Common Trade Names: Valtrex
Adult Dosing
HSV-1
- Acute episode: 2000 mg PO BID x 1 day
- Suppression: 500 mg PO daily
Genital HSV
- 1st episode: 1000 mg PO BID x 7-10 days, start within 48-72 hour of symptoms
- Recurrence: 500 mg PO BID x 3 days, alternative: 1000 mg PO daily x 5 days
Herpes zoster
- 1000 mg PO TID x 7 days
Pediatric Dosing
Genital HSV
- Same as adult dosing for adolescents
Special Populations
- Pregnancy Rating: B
- Lactation: Safe
- Renal Dosing
- Adult:
- Pediatric
- Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
- Caution with any renal impairment
- Caution with geriatric patients and reduced GFR
Adverse Reactions
Serious
- Acute renal failure
- Thrombocytopenia
- Aplastic anemia
- Delirium
- Psychosis
- Seizures
Common
- Nausea/vomiting
- Headache
- Abdominal pain
- Depression
- Elevated LFT's
- Fatigue
Pharmacology
- Half-life: < 30 minutes
- Metabolism: GI tract, liver
- Excretion: feces, urine
- Mechanism of Action: DNA polymerase Inhibitor